Lorlatinib trials for ALK-positive Non-small Cell Lung Cancer

All Lorlatinib trials · All ALK-positive Non-small Cell Lung Cancer trials

Phase breakdown

Recruiting trials studying Lorlatinib for ALK-positive Non-small Cell Lung Cancer

• AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
  NCT07617337 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
  NCT06361589 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
  NCT07784959 · Phase: Phase 1 · Ages: No age limits stated · Sex: All (male and female) · 1 location

Common questions

How many trials study Lorlatinib for ALK-positive Non-small Cell Lung Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.